Find policies, billing codes, payers, states, and providers
Pathogen Panel Testing
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Rules for outpatient pathogen panel diagnostic testing (multiplex PCR and antigen panels) including indications, limitations, and which panels meet or do not meet coverage criteria for Oscar Health members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Multiplex Pathogen Panels
inv-01: Outpatient gastrointestinal and respiratory panel coverage
Covered when the listed conditions are met in the outpatient setting:
Outpatient setting only; see Note 1 for respiratory symptoms definition
See Note 1 for respiratory signs and symptoms
Immunocompromised population only
inv-02: Panels that do NOT meet criteria
The following molecular or multiplex panel tests in the outpatient setting do NOT meet criteria:
Lack of evidence for benefit in outpatient setting
Exception: immunocompromised individuals may receive panels up to 25 targets
Not covered in outpatient setting per this policy portion; see CNS criteria for exceptions when CSF findings support testing
Not covered for outpatient use per policy portion
Examples cited include GENETWORx molecular UTI and wound tests
inv-03: CNS panel medical necessity
Molecular CSF testing (meningitis/encephalitis panel) is clinically appropriate when CSF findings and clinical presentation indicate a moderate-to-high pre-test probability.
Testing in absence of supportive CSF findings increases false positives and reduces predictive value; negative multiplex results do not exclude some encephalitides; consider adjunct serology or specific NAATs as needed
inv-04: Respiratory panel coverage criteria
Respiratory multiplex testing should be targeted to scenarios where results will change management.
In immunocompetent outpatients with mild/moderate illness prefer point-of-care influenza/RSV/SARS-CoV-2 testing due to greater demonstrated clinical impact
inv-05: Sepsis panel coverage criteria
Sepsis and bloodstream infection molecular testing is reasonable as an adjunct to blood culture when rapid identification will affect the choice or timing of therapy.
These assays shorten time to organism/resistance identification and can promote judicious antibiotic use; use as adjunct to, not replacement for, culture when required
inv-06: GI and UTI panel coverage criteria
Gastrointestinal and UTI panels have higher analytic sensitivity but variable impact on clinical outcomes; use where etiologic diagnosis will influence treatment or public health actions.
Some studies show improved organism detection but mixed evidence on improved downstream clinical outcomes
inv-07: Gastrointestinal: medically necessary contexts
Covered when ALL of the following are met for gastrointestinal multiplex testing
IDSA 2024 guidance supports testing in these contexts; avoid testing for self-limited non-inflammatory diarrhea
inv-08: C. difficile: testing algorithm and indications
Covered when ALL of the following are met for C. difficile testing
ACG and IDSA/SHEA recommend multistep algorithms and discourage repeat testing
inv-09: Respiratory: when multiplex testing is appropriate
Covered when ANY of the following are met for respiratory multiplex testing
IDSA: optional for mild outpatient CAP; prioritize testing in high-risk patients
inv-10: Central nervous system: NAAT testing
Covered when ALL of the following are met for CNS testing
IDSA recommends CSF NAAT for enteroviral CNS infection and cautions that some targets require specific assays
inv-11: Genitourinary: multiplex testing in high-risk patients
Covered when ALL of the following are met for genitourinary/STI panels
IDSA: increases detection in high-risk populations
inv-12: Laboratory validation and diagnostic stewardship
Implementation considerations
Joint AMP/ASM/IDSA/PASCV report 2023 emphasizes diagnostic stewardship and demonstration of clinical utility
inv-13: Respiratory testing recommendations
Guidance and specialty recommendations relevant to test ordering
ASCP and CDC guidance quoted in policy; order panels only when results will change management
inv-14: Solid organ transplant — GI multiplex panels
Transplant patient guidance
American Society of Transplantation Infectious Diseases COP recommendation
inv-15: C. difficile interpretation caution
C. difficile and multiplex testing caution
CDC warns that molecular assays can be positive in asymptomatic persons and to read multiplex results with caution
The policy specifies that molecular detection-based panel testing of urine pathogens for diagnosis of urinary tract infections (e.g., GENETWORx Molecular PCR UTI Test) DOES NOT MEET CRITERIA for outpatient coverage. This exclusion applies to molecular or multiplex urine panels intended to diagnose UTI because available literature does not demonstrate required clinical benefit in the outpatient setting.
The policy discourages routine use of broad, expanded multiplex respiratory panels in immunocompetent outpatients with mild or moderate illness because results for non-influenza pathogens rarely change management. It favors targeted, point-of-care testing for high-impact pathogens (for example, influenza A/B, RSV, SARS‑CoV‑2) and allows expanded panels primarily when they will alter clinical decisions or in higher-risk populations.
Routine multiplex panel testing is not recommended for self-limited, non-inflammatory outpatient infections (for example, uncomplicated acute cough or uncomplicated UTIs) where diagnostic testing is unlikely to change treatment. Professional guidance advises withholding broad microbiologic testing unless results would influence therapeutic approach.
The European Association of Urology guidelines for uncomplicated and complicated urinary tract infections recommend bacterial culture or dipstick testing and do not reference routine molecular multiplex testing in the diagnostic algorithm, implying molecular panels are not endorsed for routine UTI diagnosis.
In the policy's evidence references section there are no explicit exclusions listed beyond the guidance already stated in the coverage and exclusions sections.
The policy considers broad multiplex testing (for example, large gastrointestinal or respiratory panels) not medically necessary in many outpatient contexts due to limited evidence of clinical benefit, potential to detect colonization or prolonged shedding, and minimal impact on management for immunocompetent patients. For GI panels, the policy limits outpatient coverage to panels of up to 11 targets no more often than once every 7 days; larger GI panels (≥12 targets) do not meet criteria.
Expanded multiplex respiratory panels as first-line testing in low-risk, immunocompetent outpatients with mild respiratory illness are generally discouraged because detection of non-influenza targets rarely affects clinical decision-making. The policy recommends preferring targeted testing for influenza/RSV/SARS‑CoV‑2 and reserving broader NAAT panels for immunocompromised, critically ill, or otherwise high-impact situations.
Use of multiplex panels to detect Clostridioides difficile or other pathogens in settings with low pre-test probability (asymptomatic individuals, routine screening, or when a positive NAAT likely represents colonization) is discouraged. For C. difficile the CDC cautions that molecular assays can be positive in asymptomatic individuals and multiplex results should be interpreted with caution.
Professional societies (ASCP/ChoosingWisely, CDC) recommend against routine ordering of broad respiratory pathogen panels when results will not affect patient management. Such routine orders in low‑risk outpatient settings are discouraged because they may not change therapy and can contribute to over-testing and excess cost.
Within the evidence references section itself, the policy notes that there are no additional explicit 'not medically necessary' statements beyond those detailed in the coverage and not medically necessary sections.
Procedure and Proprietary Codes
| BioFire FilmArray RP2.1 | FDA-approved respiratory panel detecting 18 viral and 4 bacterial pathogens (includes SARS-CoV-2) |
| GenMark ePlex Respiratory Pathogen Panel / RP2 | FDA-approved respiratory pathogen panels (viral and bacterial targets) |
| BioFire FilmArray Meningitis/Encephalitis panel | FDA-approved panel detecting 14 CNS pathogens from CSF |
| T2Bacteria Panel | FDA-cleared direct-from-blood sepsis bacterial panel detecting common sepsis pathogens including ESKAPE |
| Cobas ePlex BCID panels (GP, GN, FP) | FDA-cleared blood culture identification panels for gram-positive, gram-negative, and fungal targets plus resistance genes |
| BioFire FilmArray BCID/BCID2 | Blood culture identification panels (expanded to 43 targets in BCID2) |
| MicroGenDX UroKEY | NGS-based UTI panel claiming detection of >57,000 bacteria and fungi |
| Pathnostics Guidance® UTI | PCR + pooled antibiotic susceptibility test identifying 27 organisms and 32 resistance genes |
| 0142U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected |
| 0202U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including SARS-CoV-2, qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected |
| 0115U | Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, each analyte reported as detected or not detected (ePlex Respiratory Pathogen Panel) |
| 0068U | Candida species panel, amplified probe technique, qualitative report of presence/absence of each species (MycoDART-PCR) |
| 0442U | Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification (MSCSF) |
| 0441U | Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis |
| 0564U | BioFire® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel - Respiratory/Sore Throat menu (upper respiratory specimen) each pathogen reported as positive or negative |
| 0590U | Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism (BIOTIA-ID Urine NGS Assay) |
| 0593U | Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected |
| unspecified CPT descriptors | Infectious agent detection by nucleic acid (DNA or RNA); panels described by target ranges (3-5, 6-11, 12-25 targets) for gastrointestinal and respiratory pathogens; antigen detection codes for combined SARS-CoV-2 and influenza A/B and/or RSV |
Provider Actions, Prior Authorization & Documentation
Outpatient testing authorization note
This policy applies to outpatient testing and specifies which multiplex panels meet or do not meet coverage criteria; authorization may be required per the member's benefit and the policy guidance should be used when requesting coverage.
Respiratory panel prior authorization guidance
Prior authorization is appropriate for broad, expanded multiplex respiratory panels when clinical documentation does not demonstrate a high pre-test probability or when multiple low-impact targets unlikely to change management are requested; targeted tests for high-impact pathogens (influenza A/B, RSV, SARS‑CoV‑2) are preferred.
Prior authorization for low-risk outpatient panel orders
Prior authorization is required when multiplex panels are ordered for low-risk outpatients or routine screening without documented high-risk features; panels intended primarily for hospitalized, immunocompromised, or critically ill patients are more likely to be authorized.
Use listed procedure codes for authorization
Use the specific CPT/HCPCS and proprietary laboratory test codes listed in the policy (including multiple proprietary U-codes and panel descriptors) when requesting authorization or submitting claims; reference the exact code corresponding to the panel performed.
Prior authorization
No prior authorization requirements are specified in the evidence references and publication history section of this policy.
Step therapy
No step therapy requirements are specified in this portion of the policy.
Prefer targeted respiratory testing first
Favor targeted point-of-care testing for influenza, RSV, and SARS‑CoV‑2 before ordering larger multiplex respiratory panels in immunocompetent outpatients with mild to moderate illness, because point-of-care influenza testing has greater demonstrated impact on clinical outcomes.
C. difficile multistep testing
For suspected C. difficile infection, perform testing only for patients with diarrhea (≥3 unformed stools in 24 hours) and follow a multistep algorithm pairing a highly sensitive assay (NAAT or GDH) with a more specific toxin EIA rather than NAAT alone.
- Test stool only from patients with ≥3 unformed stools in 24 hours.
- Use NAAT or GDH first paired with toxin EIA as the second step.
Conservative testing preferred
Do not routinely order broad respiratory pathogen panels unless the result will affect patient management; conservative use is recommended by ASCP/ChoosingWisely.
Step therapy (none specified)
No step therapy requirements are specified in this section of the policy.
Documentation and coding
Providers must submit accurate documentation of services performed and code claims according to industry standard coding guidelines; failure to follow appropriate coding/billing guidelines or current reimbursement policies may result in denial or recoupment.
- Document services and select codes per CPT/HCPCS and industry standards.
- Claims may be denied or recouped if documentation or coding is inaccurate.
CSF pre-test screening documentation
Before ordering molecular CSF testing, document CSF cell count, glucose, and protein analyses as screening; elevated leukocyte count or protein or heightened clinical suspicion (e.g., suspected HSV encephalitis) should be recorded to support molecular testing.
Blood culture adjunct documentation
When multiplex PCR is used as an adjunct after a positive blood culture, document the positive culture and clinical rationale (for example, prior antibiotic exposure or need for rapid identification) to justify molecular testing.
C. difficile test documentation
For C. difficile testing, document the presence of diarrhea (≥3 unformed stools in 24 hours) and that testing follows a multistep algorithm (NAAT/GDH plus toxin EIA); avoid repeat testing and record clinical signs consistent with active CDI.
- Document ≥3 unformed stools in 24 hours.
- Document use of a multistep testing algorithm (NAAT/GDH + toxin EIA).
- Avoid and document that repeat testing is not performed.
Document clinical justification for multiplex panels
Document clinical justification and relevant risk factors when ordering multiplex panels (for example: hospitalization, immunocompromise, persistent or severe symptoms, travel/exposure for parasites, or outbreak settings) to support medical necessity.
Procedure coding documentation
Document the specific test performed using the CPT/HCPCS and proprietary codes listed in the policy (including proprietary U-codes and panel descriptors) to support billing and coverage determinations.
Evidence/publication documentation note
This evidence references section and the publication history do not specify additional provider documentation or submission requirements.
Coding and documentation risk
Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed and if documentation is inaccurate.
Non‑covered panel triggers
Tests designated as DOES NOT MEET CRITERIA in the policy—such as multiplex gastrointestinal panels with 12 or more targets and molecular panels for CSF, blood, urine, or wound—are at risk for denial.
CSF testing precondition
Ordering multiplex PCR CSF tests without correlating CSF findings (for example, elevated leukocyte count or protein) increases false positives and reduces predictive value; tests should be ordered only when moderate-to-high pre-test probability exists and supporting CSF results are documented.
Respiratory panel actionability
Broad multiplex respiratory panels in immunocompetent patients with mild or moderate illness often do not change management; use of targeted testing is favored and ordering broad panels without justification risks denial.
GI testing limited to specific clinical contexts
Gastrointestinal panel testing may be denied if performed outside the specified clinical contexts (non-inflammatory, self-limited diarrhea or short-duration gastroenteritis); reserve testing for moderate-severe, bloody/febrile/dysenteric illness, >7 days duration, nosocomial cases, or immunocompromised individuals.
Respiratory panel use limited to higher-acuity patients
Respiratory multiplex panels are expected to be targeted to hospitalized, immunocompromised, or severely ill patients; routine outpatient testing in mild CAP or low-risk outpatients may be denied.
Conflict with government policy
If there is a conflict between this policy and an applicable government policy (for example, Medicare LCDs/NCDs or state Medicaid rules), the government policy will govern coverage determinations; failure to follow applicable government policies could trigger denial.
Denial triggers (none in references)
No denial triggers are listed in the evidence references section of the policy.
Background and Policy Scope
Multiplex PCR and antigen panels permit detection of multiple pathogens from a single specimen and are generally more sensitive and faster than many conventional methods. Antigen panels are less sensitive but useful for rapid, point‑of‑care testing; expanded molecular panels have higher diagnostic yield but can detect colonization or prolonged shedding, which may limit clinical utility in many outpatient populations.
Definitions and Abbreviations
Revision History & References
No explicit exclusions are listed in the evidence references portion of the policy beyond the specific exclusions and not‑medically‑necessary determinations already described elsewhere in the document.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.